Browse by author
Lookup NU author(s): Simon Cotterill,
Professor John Lunec,
Professor Andrew Pearson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Histological sections from 231 patients with neuroblastoma were reviewed and morphological features and their relationship to age, stage, MYCN amplification (in 128 trumours by Southern analyses), and clinical outcome (based on Shimada risk grouping) determined. Stage 4 disease was associated with poorly differentiated and undifferentiated tumours (P = 0.001), an MKI of >2% (P < 0.001), and Shimada unfavourable histology (UHi) P < 0.0001. In univariate analysis MKI was significant in predicting a poorer relapse-free survival (RFS), low vs. intermediate and high (P < 0.001). Age, MYCN amplification, and Shimada UH also emerged as significant variables. There was a higher proportion of MYCN-amplified tumours with Shimada UH (P = 0.03), and this group had a decreased RFS (P = 0.002). In patients with Shimada FH, MYCN amplification did not significantly predict a poor prognosis. In those with stage 4 disease, Shimada classification was not significant in predicting survival (P = 0.97); the same was true for those over the age of 1 year (P = 0.66). In multivariate analysis, MYCN amplification and Shimada UH both emerged as independent prognostic factors. In conclusion, morphological features assigned some subsets of patients to prognostic risk groups. Most MYCN-amplified rumours have unfavourable histology and a poorer prognosis. However, in patients with stage 4 disease and those over the age of 1 year, other factors that may influence prognosis should be determined. Med. Pediatr. Oncol. 36:169-176, 2001. (C) 2001 Wiley-iiss, Inc.
Author(s): George, R.E., Variend, S., Cullinane, C., Cotterill, S.J., McGuckin, A.G., Ellershaw, C., Lunec, J., Pearson, A.D.J.
Publication type: Article
Publication status: Unknown
Journal: Medical and Pediatric Oncology
ISSN (print): 1545-5009
ISSN (electronic): 1545-5017
Altmetrics provided by Altmetric